Particle.news

Download on the App Store

Preclinical Studies Reverse Alzheimer’s Deficits by Targeting Cholesterol Uptake and Lithium Levels

Researchers are urging controlled clinical trials to establish safety, dosing and effectiveness following mouse studies that reversed Alzheimer’s pathology

Image
Ilustrativa
El equipo científico liderado por Lucas J. Sosa se completa con las científicas Valentina Gesto y Romina Aimar.
Image

Overview

  • Researchers at Barcelona’s Hospital de Sant Pau found that the APOE4 genetic variant impairs neuronal uptake of cholesterol, as detailed in the August 6 Journal of Lipid Research publication.
  • Harvard Medical School scientists showed that amyloid plaques sequester lithium in the brain, leading to accelerated plaque formation and cognitive decline in mouse models.
  • A lithium orotate formulation evades plaque sequestration, restores natural brain lithium levels and reverses memory loss and neuropathology in Alzheimer’s mice without traditional lithium side effects.
  • The Global Neurodegeneration Proteomics Consortium’s open-access archive and recent Alzheimer’s Association grants to CONICET labs are guiding exploration of these molecular targets.
  • Experts emphasize the preliminary nature of these findings and call for controlled human trials to evaluate safety, dosing and therapeutic impact.